Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tildacerfont versus placebo in adults with major depressive disorder
ISRCTN73588250Phase 2Completed
- Sponsor
- MAC Clinical Research
- Start
- Jul 2025
- Modality
- Small Molecules
01
Overview
Phase 2, randomised, double-blind trial in major depressive disorder (MDD) comparing Tildacerfont with Placebo (2 arms). Primary endpoint: Hamilton Depression Rating Scale 17-item total score at Day 42. Started Jul 2025; status: completed.
02
Drugs
tildacerfont
03
Conditions
major depressive disorder (MDD)
Beyond the preview
Go deeper on ISRCTN73588250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN73588250.